Clinical Trial

Methotrexate Therapy and High-Resolution CT Chest and Spirometry Test Findings in Patients With Rheumatoid Arthritis.

Completed
View on ClinicalTrials.gov →
Summary
ABSTRACT Background: Rheumatoid arthritis (RA) is characterized by symmetrical erosive synovitis and progressive disability, often complicated by extra-articular manifestations especially in seropositive patients, among them, lung involvement is common, and it can include a wide spectrum of disorders, ranging from airways, pleural disease, bronchiectasis, lung nodules, to infection. Aim of the Work: The aim of this study is to assess HRCT Chest and spirometry test findings in RA Egyptian patients, and their relationship to Methotrexate therapy, disease duration, and activity. Patients and Methods: This was a cross sectional study which was done on 50 RA patients diagnosed according to Rheumatoid Arthritis - 2010 American college of rheumatology/ European League Against Rheumatism (ACR-EULAR) attending rheumatology and chest inpatient departments and outpatient clinics in Ain Shams University Hospitals. Results: Patients were divided into two equal groups: Group A: - 25 RA patients treated with MTX only +/- low dose steroid. Group B: - 25 MTX naive RA patients (treated with DMARDs other than MTX) +/- low dose steroid. Conclusion: We found MTX has no role in RA-ILD, there is no significant difference between MTX users and MTX naïve regarding spirometry and HR-CT.
Trial Details
NCT Number NCT07360340
Lead Sponsor Ain Shams University
Conditions Methohexitone Pulmonary Adverse Reaction
Enrollment 50 participants
Start Date 2022-12-01
Primary Completion 2023-06-30 (estimated)
Study Completion 2023-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-22